43 results about "Vein occlusion" patented technology

Methods and devices for relieving stenoses in, or otherwise improving blood flow through, body lumens. Although applicable in a variety of different body lumens, the methods and devices of this invention are specifically useable for relieving stenoses in, or otherwise improving blood flow through, veins which drain blood from the brain for treatment of multiple sclerosis or other neurodegenerative disorders that are caused, triggered or exacerbated by venous occlusion or venous insufficiency.

Systems and methods are described providing for the use of ultrasound energy to effect the dislodging of one or more blood clots inside blood vessels. Such clots can include those inside retinal vessels, especially in patients with central retinal vein occlusion. Embodiments of the present disclosure may be used for any retinal arterial or venous occlusion. In exemplary embodiments, a small probe can be inserted into the eye of a patient and placed over the retinal vessels. Acoustic streaming created by the probe can be directed to an area or region including targeted blood vessels, resulting in increased flow in one or more retinal veins and facilitating or effecting mechanical dislodging of one or more blood clots in the targets blood vessels. Exemplary embodiments can utilize ultrasonic energy produced at a frequency of approximately 44 MHz to 46 MHz with pulse repetition frequencies of approximately 100 Hz to 100 kHz.

A medical system, comprising an ablation catheter is disclosed. The ablation catheter includes an elongate shaft with a proximal end, a distal end and a lumen disposed between the proximal end and the distal end. The ablation catheter also includes an expandable element in fluid communication with the lumen, a first temperature sensor operable to measure a first temperature; and a second temperature sensor operable to measure a second temperature. The first temperature sensor and the second temperature sensor are longitudinally separated from each other by at least a portion of the expandable element.

The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of multiple doses of a VEGF antagonist to a patient at a frequency of once every 8 or more weeks. The methods of the present invention are useful for the treatment of angiogenic eye disorders such as age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.

The invention discloses water soluble puerarin derivatives shown in general formulas (I) and (II), a preparation method thereof, a medicinal composition containing one or more compound compositions, and application of the compounds in preparing medicaments for treating diseases such as cardiovascular and cerebrovascular diseases, retinal artery and vein occlusions, diabetes and the like.

The present invention discloses the puerarin derivatives, and their preparation process, medicine compositions and application in preparing medicine for treating cardiac and cerebral vascular diseases, obstruction of retinal artery and vein, sudden hearing loss and other diseases, improving memory and lowering blood sugar.

The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of multiple doses of a VEGF antagonist to a patient at a frequency of once every 8 or more weeks. The methods of the present invention are useful for the treatment of angiogenic eye disorders such as age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.

The invention provides a novel retrievable vena cava thrombus multi-filtering device. The multi-filtering device is composed of a retrieve hook, a connecting internal nut, a forked type filter screen, blood vessel fixing stabs, a sine wave filter screen, a tail end and a tail end connecting nut. The structure of the multi-filtering device is formed through integrated cutting processing and welding by adopting laser. The product is in a double-saucer-shaped structure, so that the contact area of the product and the vascular wall is obviously reduced, the intimal hyperplasia area of the vascular wall is greatly reduced, and when the multi-filtering device is retrieved, the damage to the vascular venous wall is obviously reduced, thus the retrievable time of the product in the human body is obviously prolonged. The double-saucer structure of the product is provided with four filtering screens, so that the thrombus filtering times can be increased, the thrombus filtering efficiency can be improved, while the thrombus is filtered, the passing of the blood is not blocked, therefore, the relapse risk of pulmonary embolism and the risk of the vein occlusion after the patient is treated by adopting the thrombus filtering device is greatly reduced.

Provided are a pancreas perfusion apparatus capable of administering a drug only to the pancreas and strictly suppressing a leakage of the drug outside the pancreas and a method for controlling the same. The apparatus includes: a first vein occlusion section occluding a vein through which a venous blood from the pancreas flows; a second vein occlusion section occluding a vein into which a venous blood from collateral pathways outside the pancreas flows; an artery occlusion section occluding sites where an artery that nourishes the pancreas is connected to arteries that nourish other tissues; a drug administration section recovering a liquid upstream of the first vein occlusion section and supplying the recovered liquid to the artery; a systemic circulation section recovering a liquid upstream of the second vein occlusion section and feeding the recovered liquid into a systemic circulation; and a control device controlling the systemic circulation pump.

The invention discloses a detection method for eyeground multi-disease classification based on deep learning. The method comprises the steps of obtaining an eyeground image, and selecting a training set and a test set according to independent identically-distributed conditions; preprocessing and enhancing the eyeground image, and extracting eyeground color photo image features; establishing a convolutional neural network model based on an EffecientNet + Attention Module, and adjusting the network structure; initializing network parameters by using a migration learning mode; based on the extracted eyeground features, training a detection model on a training set by using a reverse gradient propagation mode in deep learning, and finely adjusting parameters of the detection model; and finally,obtaining a detection model capable of distinguishing eight classifications including normal eyeground, high myopia, glaucoma, maculopathy, vein occlusion, diabetic retinopathy, hypertensive retinopathy and other degeneration. According to the detection method disclosed by the invention, automatic detection for multiple diseases of patients with eyeground diseases is realized, and the detection method is high in precision and high in speed.

The invention relates to a capsule for treating retinal vein occlusion. The capsule is characterized in that scutellaria, gegen, salvia, rehmanniae vaporata, cornus officinalis, moutan cortex, white peony root, chrysanthemum, angelica, medlar, dandelion and glycyrrhiza undergo the extraction of concentrated liquid, the concentrated liquid is prepared into extract powder, the extract powder is mixed with centipede powder, scorpion powder, eupolyphaga sinensis powder, long-nosed pit viper powder and pearl powder and stirred evenly, the mixture is subject to drying, sterilization and encapsulating, and the capsule for treating retinal vein occlusion is finally obtained.

The invention discloses a medicine used for curing the diseases such as coronary heart disease, angina, miocardial infarction, retinal artery or vein occlusion and sudden deafness, etc. and a preparation method thereof. The invention aims at making up the deficiency of the prior art and provides a puerarin sustained-release pill preparation. In the constituents adopted by the prior art, the puerarin sustained-release pill related by the invention utilizes hydrophilic framework material and hydrophobic framework material as stroma and is added with stabilizing agent vitamin C, so as to effectively overcome the defects of the prior art and ensure that the medicaments do not have apparent change relating to the material contents within the valid storing period; furthermore, the puerarin sustained-release pill has the advantages of enough medicine release, controllable medicine releasing time, few times needed by the patient to take the medicine, long time for taking effect and high bioavailability, and is suitable for clinic and family.

The invention discloses a novel retrievable vena cava thrombus filter. The product is composed of a retrieving hook, a connecting internal nut, front-end filter screens, blood vessel fixed thorns, balancing pillars, sine wave filter screens, a tail end and a tail end connecting nut. The filter structure is formed through integrated laser cutting processing and welding. The finished product disclosed by the invention, by virtue of the sine wave filter screens in positive S forms, can expand the filter part of the filter and improve the thrombus filter efficiency; the product, when used for filtering thrombus, can avoid occlusion in the passing ability of blood flow, so that the risks of pulmonary embolism reoccurrence and vein occlusion in a patient subjected to the treatment by virtue of the thrombus filter apparatus. The product, which is processed from same nickel-titanium alloy, can improve the corrosion potential thereof, relieve the corrosion thereof in blood, relieve the invasion of metal ions into a human body and promote the safe use thereof.

A device for treatment of venous congestion provides for subcutaneous introduction of anticoagulant through an incision positioned within a collection shell for withdrawal of an effused material. A widened delivery tip provides dispersal of the anticoagulant and may be agitated to disrupt clot formation.

This invention relates to the use of a heparanase inhibitor for treating, or inhibiting the progression or development of, an ocular inflammatory disorder, such as age-related macular degeneration, diabetic retinopathy, retinitis pigmentosa, retinal 5 vein occlusion, retinoblastoma, uveitis, macular edema, dry eye, ocular inflammation associated with an infection or keratoconus.

Provided is a medicine for preventing or treating an ophthalmic disease associated with enhanced intraocular neovascularization and / or intraocular vascular permeability. The present inventors have made studies on medicines for preventing or treating ophthalmic diseases associated with enhanced intraocular neovascularization and / or intraocular vascular permeability. As a result, it is confirmed that a selective S1P receptor agonist having an agonistic activity on a S1P1 receptor has an activity to prevent intraocular neovascularization and an activity to prevent intraocular vascular permeability, and the present invention is accomplished. A compound according to the present invention, which is a selective S1P receptor agonist having an agonistic activity on a S1P1 receptor or a pharmaceutically acceptable salt thereof has an activity to prevent intraocular neovascularization and intraocular vascular permeability, and can be used as a prophylactic and / or therapeutic agent for exudative age-related macular degeneration, diabetic retinopathy, diabetic macular edema, myopic choroidal neovascularization, retinal artery occlusion, retinal vein occlusion, neovascular glaucoma or the like.

The invention relates to a puerarin sodium phosphate injection and a preparation method thereof. The puerarin sodium phosphate injection comprises puerarin sodium phosphate, a preservative, an isoosmotic adjusting agent, a pH value adjusting agent, an antioxygen, a local analgetic and injection water, wherein due to the addition of the antioxygen, the stability of the puerarin sodium phosphate injection can be improved, and due to the addition of the local analgetic, the pain of a patient can be lightened and no influence is caused to a main drug. The preparation method of the puerarin sodium phosphate injection mainly comprises the steps: weighing, dissolving, adsorbing a heat source by active carbon, filtering, metering volume, end-filtering, sub-packaging, plugging and covering. The puerarin sodium phosphate injection is used for adjuvant therapy of the coronary heart disease, the stenocardia, the myocardial infarction, the retina artery and vein occlusion, sudden deafness, ischemic cerebrovascular disease and the like. The puerarin sodium phosphate injection is stable in quality, accurate in treatment effect, and beneficial to acceptation by a patient.

The invention relates to a method and device for reducing the intraocular VEGF concentration. The device is used for measuring the VEGF concentration by taking vitreous cavity liquid after the vitrectomy; when the intraocular VEGF concentration is increased, the device is also used for changing and washing the vitreous cavity liquid to reduce the VEGF concentration to prevent and treat a series ofintraocular neovascular diseases secondary to various diseases such as diabetic retinopathy, retinal vein occlusion and the like. The device can be retained in eyeballs for a long time during the treatment of eye diseases, and be taken out after the end of the intraocular treatment.

Anti-apelin antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, and methods of producing the antibodies and using the antibodies for treating or preventing diseases such as diabetic retinopathy (DR), including proliferative diabetic retinopathy (PDR) and non-proliferative diabetic retinopathy (NPDR), age-related macular degeneration (AMD), diabetic macular edema (DME), macular edema following retinal vein occlusion (RVO), retinal degeneration, myopic choroidal neovascularization (mCNV), diabetic nephropathy, chronic kidney disease (CKD), non-alcoholic steatohepatitis (NASH), liver cirrhosis, plaque neovascularization, rubeosis iridis, neovascular glaucoma, corneal neovascularization (CNV), retinopathy of prematurity (ROP), retinopathy, macular degeneration, ovarian hyperstimulation syndrome (OHSS), uterine bleeding, endometriosis, endometrial hyperplasia and cancer, myometrial leiomyomas, adenomyosis, cancer (e.g., solid tumors and hematologic malignancies), fibrosis, and / or associated complications.

The invention discloses a pen-type venous occlusion device. The device comprises a scanning probe, a casing, a controller, a liquid crystal screen, a battery pack and a control switch, wherein the scanning probe is arranged at the front end of the casing, a pressure sensor is arranged on the surface of the scanning probe, and an ultrasonic transducer is arranged in the scanning probe; the liquid crystal screen is arranged on the outer surface of the upper part of the casing, and the control switch is arranged at the top end of the casing; the pressure sensor, the ultrasonic transducer, the liquid crystal screen and the control switch are respectively connected with controller which is arranged inside the casing; the battery pack is arranged in the casing and connected with the controller. The pen-type venous occlusion device is novel in structure and convenient to use, can be used for observing the situation of blood vessels and preventing angiectopia of neck, oxter or other parts during PICC or port-cath cathetering, can be used when PICC or port-cath ectopia is treated by a finger-press method, can be used for assisting a doctor to observe the situation of venous occlusion and pressing occluded veins by proper pressure according to requirement, so that ectopic catheter or port-cath is restored to a normal position.

The invention discloses a new compound containing an anthracycline structure as well as a preparation method and application of the new compound containing the anthracycline structure. The anthracycline antibiotic, namely the new compound containing the anthracycline structure, is coupled with non-linear multi-segmented copolymer and has better effect in treatment of a retina vein occlusion disease compared with medicines or medicaments in other forms.

Provided is a pharmaceutical for preventing or treating an ophthalmic disease associated with intraocular neovascularization and / or increased intraocular vascular permeability. The inventors of the present invention have made investigations on a pharmaceutical for preventing or treating an ophthalmic disease associated with intraocular neovascularization and / or increased intraocular vascular permeability, and have confirmed that a selective S1P receptor agonist having agonist activity at an S1P1 receptor has an intraocular neovascularization-reducing action and an intraocular vascular permeability-reducing action, thus completing the present invention. A compound or a pharmaceutically acceptable salt thereof of the present invention, which serves as the selective S1P receptor agonist having agonist activity at the S1P1 receptor, has an intraocular neovascularization-reducing action and an intraocular vascular permeability-reducing action, and can be used as a preventive and / or therapeutic agent for, for example, exudative age-related macular degeneration, diabetic retinopathy, diabetic macular edema, myopic choroidal neovascularization, retinal artery occlusion, retinal vein occlusion, or neovascular glaucoma.

The present disclosure relates to fusion molecules and chimeric molecules which comprise two components: an Ang-2 antagonist peptide linked to a VEGF-binding moiety. Further disclosed are methods of using said chimeric molecules to treat a patient cancer, proliferative retinopathy, neovascular glaucoma, macular edema, wet age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), or diabetic retinopathy (DR).

The invention discloses a common medication method for treating retinal artery and vein occlusion, and relates to the field of medical medicines. The common medication method for treating retinal artery and vein occlusion has an obviously better effect than other medicines and methods for treating the retinal artery and vein occlusion. The common medication method has the advantages of convenience in use, no side effects, no strict requirement of the time, effectiveness to patients with advanced retinal artery and vein occlusion, promotion of recovery of retina neuron, and thrombus dissolving and blood vessel blood flow volume increasing effects.

The invention discloses a traditional Chinese medicine composition for treating hemorrhagic eye diseases and a preparation method of the traditional Chinese medicine composition, relates to the technical field of traditional Chinese medicines, and aims at solving the problems that the hemorrhagic eye diseases including macular degeneration, retinal vein occlusion and the like have retinal blood circulation disturbance of different degrees, tissue blood supply is insufficient, abnormal blood vessels are generated, and lesions are caused. The traditional Chinese medicine composition is mainly used for improving eyesight, activating blood circulation to dissipate stasis, promoting and improving retinal blood circulation, dredging blood vessels, increasing blood supply, improving ischemia andanoxia conditions of tissues and promoting absorption of bleeding, edema, exudation and fibroproliferative organized tissues, so as to achieve a treatment effect.

The invention discloses application of antiplatelet thrombolysin to preparation of a medicine for treating retinal vein occlusion diseases, and is characterized in that the antiplatelet thrombolysin consists of two peptide chains, including an alpha chain and a beta chain, and the amino acid sequence of the alpha chain is as shown in SEQ ID NO.1, and the amino acid sequence of the beta chain is as shown in SEQ ID NO.2. According to the application of the antiplatelet thrombolysin to the medicine provided by the invention, photochemical method-induced retinal vein occlusion can be obviously improved, the choriocapillaris filling phase is shortened, and vascular recanalization is promoted, thus being beneficial to improvement and treatment of the retinal vein occlusion; and the antiplatelet thrombolysin has a good clinical application prospect.

A method and device for reducing the concentration of VEGF in the eye. This device is used for measuring the concentration of VEGF by taking the liquid in the vitreous cavity after vitrectomy; Reduce the concentration of VEGF, prevent and treat a series of intraocular neovascular diseases secondary to various diseases such as diabetic retinopathy and retinal vein occlusion. The device can indwell the eyeball for a long time during the treatment of eye diseases, and take it out after all the intraocular treatments are finished.

A system and a method are disclosed for treating hepatic area vein occlusion problem. There are five major techniques, used in combined manner or separately, showing effective cure rate. The first technique is to use multiple types of guiding wire through-to-through skills. The second technique is to use one or more accessory hepatic veins (AHV) to drain hepatic blood into inferior vena cava for decreasing pressure inside the liver. The third technique is to puncture through occlusion of veins. The fourth technique is reverse direction membrane puncture. The fifth technique is thrombosis handling.